Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO101 topical gel for atopic dermatitis with Staphylococcus aureus colonization
ACTRN12607000447459Phase 2Terminated
- Sponsor
- Neosil
- Start
- Sep 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NEO101 in atopic dermatitis (AD), sponsored by Neosil. Started Sep 2007; status: terminated.
02
Drugs
NEO101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ACTRN12607000447459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000447459.